ABIVAX Société Anonyme AAVXF Stock
ABIVAX Société Anonyme Price Chart
ABIVAX Société Anonyme AAVXF Financial and Trading Overview
| ABIVAX Société Anonyme stock price | 10.95 USD |
| Previous Close | 16.5 USD |
| Open | 16.5 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 16.5 - 16.5 USD |
| 52 Week Range | 5.79 - 25.6 USD |
| Volume | 1K USD |
| Avg. Volume | 117 USD |
| Market Cap | 728.7M USD |
| Beta (5Y Monthly) | 1.321072 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.68 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AAVXF Valuation Measures
| Enterprise Value | 717.39M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7287.0273 |
| Price/Book (mrq) | 42.307693 |
| Enterprise Value/Revenue | 7173.892 |
| Enterprise Value/EBITDA | -12.722 |
Trading Information
ABIVAX Société Anonyme Stock Price History
| Beta (5Y Monthly) | 1.321072 |
| 52-Week Change | -35.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 25.6 USD |
| 52 Week Low | 5.79 USD |
| 50-Day Moving Average | 15.12 USD |
| 200-Day Moving Average | 9.67 USD |
AAVXF Share Statistics
| Avg. Volume (3 month) | 117 USD |
| Avg. Daily Volume (10-Days) | 120 USD |
| Shares Outstanding | 42.32M |
| Float | 17.5M |
| Short Ratio | N/A |
| % Held by Insiders | 2.46% |
| % Held by Institutions | 50.57% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -56646.00000000000000000000000000000000% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.54% |
| Return on Equity (ttm) | -315.23% |
Income Statement
| Revenue (ttm) | 100K USD |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 100K USD |
| EBITDA | -56388668 USD |
| Net Income Avi to Common (ttm) | -69846000 USD |
| Diluted EPS (ttm) | -3.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.95M USD |
| Total Cash Per Share (mrq) | 0.64 USD |
| Total Debt (mrq) | 46.07M USD |
| Total Debt/Equity (mrq) | 529.43 USD |
| Current Ratio (mrq) | 1.719 |
| Book Value Per Share (mrq) | 0.39 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -65579000 USD |
| Levered Free Cash Flow (ttm) | -51252376 USD |
Profile of ABIVAX Société Anonyme
| Country | United States |
| State | N/A |
| City | Paris |
| Address | 7-11 boulevard Haussmann |
| ZIP | 75009 |
| Phone | 33 1 53 83 08 41 |
| Website | https://www.abivax.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Q&A For ABIVAX Société Anonyme Stock
What is a current AAVXF stock price?
ABIVAX Société Anonyme AAVXF stock price today per share is 10.95 USD.
How to purchase ABIVAX Société Anonyme stock?
You can buy AAVXF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ABIVAX Société Anonyme?
The stock symbol or ticker of ABIVAX Société Anonyme is AAVXF.
Which industry does the ABIVAX Société Anonyme company belong to?
The ABIVAX Société Anonyme industry is Biotechnology.
How many shares does ABIVAX Société Anonyme have in circulation?
The max supply of ABIVAX Société Anonyme shares is 91.09M.
What is ABIVAX Société Anonyme Price to Earnings Ratio (PE Ratio)?
ABIVAX Société Anonyme PE Ratio is now.
What was ABIVAX Société Anonyme earnings per share over the trailing 12 months (TTM)?
ABIVAX Société Anonyme EPS is -3.68 USD over the trailing 12 months.
Which sector does the ABIVAX Société Anonyme company belong to?
The ABIVAX Société Anonyme sector is Healthcare.